Table 1.
Characteristics of study patients with CML
| Subject | Time since diagnosis, mo | WBCs × 109/L | Diagnosis | Age/sex | HLA-Cw(Bw4+) | HLA-C group | Study performed |
|---|---|---|---|---|---|---|---|
| 1 | 7 | 38 | CML-AP | 31/F | 04/07* (-) | 2/1 | 1 |
| 2 | 12 | 33.5 | CML-CP | 23/F | 05/07* (-) | 2/1 | 1,2 |
| 3 | 4 | 12 | CML-CP | 29/M | 04/05* (-) | 2/2 | 1,2,3 |
| 4 | 6 | 3.5 | CML-CP | 32/M | 03/07 (-) | 1/1 | 1,3,5 |
| 5 | 24 | 23 | CML-CP | 26/M | 04/15 (-) | 2/2 | 2,3,5 |
| 6 | 6 | 112 | CML-CP | 23/M | 07/16 (-) | 1/NA | 1,2 |
| 7 | 5 | 3 | CML-CP | 31/M | 07/17 (-) | 1/2 | 1,2 |
| 8 | 5 | 9.0 | CML-CP | 19/M | 04/04 (-) | 2/2 | 2 |
| 9 | 9 | 23 | CML-CP | 39/M | 06/07 (-) | 2/1 | 1,2 |
| 10 | 4 | 14 | CML-CP | 30/F | 7/ND (-) | 1 | 1,2 |
| 11 | 22 | 38 | CML-CP | 20/M | 04/05 (-) | 2/2 | 2,5 |
| 12 | 18 | 5.7 | CML-CP | 19/F | 04/05 (-) | 2/2 | 2 |
| 13 | 5 | 2.4 | CML-CP | 29/F | 03/08 (-) | 1/1 | 2 |
| 14 | 18 | 26 | CML-Ph- | 18/M | 02/12 | 2/1 | 1,2 |
| 15 | 9.5 | 6.8 | CML-CP | 18/F | 04/07 | 1/2 | 1,5 |
| 16 | 54 | 41.2 | CML-AP | 44/F | ND | ND | 4 |
| 17 | 6 | 5.6 | CML-CP | 28/M | ND | ND | 4 |
| 18 | 36 | 3.9 | CML-CP | 53/F | ND | ND | 4 |
| 19 | 31 | 31.7 | CML-CP | 39/F | ND | ND | 4 |
| 20 | 28 | 11.6 | CML-Ph- | 54/M | ND | ND | 4 |
| 21 | 32 | 2.5 | CML-CP | 28/F | 03/08 | 1/1 | 1,2 |
| 22 | 22 | 16.8 | CML-CP | 21/M | 06/15 (-) | 2/2 | 2 |
Due to the limited availability of the biologic material, the number of the assays performed for single patients vary.
CP indicates chronic phase; AP, accelerated phase; Ph-, Philadelphia chromosome; NA, not available; ND, not done; 1, CD34 CML for colony inhibition assays with matched and mismatched effectors with or without acid stripping; 2, CD34 CML cells for MICA/B and NKG2D labeling; 3, CD34 CML cells for cytotoxicity tests; 4, serum assay for MICA/B; 5, CD34 CML cells for proliferation assay.